Press Release (ePRNews.com) - LONDON, England - Nov 30, 2016 - Due to significant investment and promising results in early phase clinical trials for chronic and rare diseases, reports have predicted the DNA and RNA therapeutics market to reach $1.2 billion by 2020. Of the 700 DNA and RNA therapeutics that are in the drug development pipeline, nearly 35% are targeting oncology.
Hear more on cancer therapeutics next February when SMi’s 8TH annual 2017 conference on RNA Therapeutics returns to London.
Featured presentations include:
INTRAVENOUSLY INJECTABLE RNA NANOMEDICINES AS CANCER VACCINES: CASE STUDY WITH RNA-LIPOPLEXES
Heinrich Haas, RNA Formulation and Drug Development Vice President at BioNTech AG will provide new updates on the development of nucleic acid based nanomedicines. The talk will explore mRNA for cancer vaccination with detailed insight into formulation development and preclinical proof-of concept for RNA-lipoplex formulations. GMP manufacturing and clinical testing of RNA-lipoplex products will also be discussed.
THERAPEUTIC ANTISENSE OLIGONUCLEOTIDES IN ONCOLOGY
A big pharma update on clinical trials in oncology as Mark Edbrooke, Senior Principal Scientist from AstraZeneca, looks at the progress of emerging antisense oligonucleotide drugs and drug delivery methods to target “un-druggable” sites.
INDIVIDUALISED MRNA-BASED CANCER IMMUNOTHERAPY
Hear how BioNTech are driving progress in cancer immunotherapy through case study results into the first clinical experience with mRNAs in individualised cancer immunotherapy. Vice President for RNA Biochemistry & Manufacturing, Andreas Kuhn, will give insight into key topics surrounding: the optimisation of mRNA for therapeutic applications; GMP manufacturing of mRNA; and the IVAC MUTANOME concept.
Further information is available online at http://www.smi-online.co.uk/pharmaceuticals/uk/rna-therap…
8th Annual Event: RNA Therapeutics 2017
Conference: 22nd & 23rd Feb | Interactive workshop: 21st Feb
Copthorne Tara Hotel, Kensington, London, UK
— end —
For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: firstname.lastname@example.org
To register for the conference, visit http://www.smi-online.co.uk/pharmaceuticals/uk/rna-therapeutics
Redirect to a different website not supported. Please use the final URL or contact Fateja Begum on
Tel: +44 (0)20 7827 6184 / Email: email@example.com
To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 /
* Source http://www.genengnews.com/insight-and-intelligence/rna-based-therapeutics-and-vaccines/77900520Email: firstname.lastname@example.org
About SMi Group: Source :
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk